The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.

Modestly lower risk for depression seen compared with DPP-4i use, but not compared with SGLT-2i use. (HealthDay News) — For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 ...

A recent study published in eClinical Medicine compares the effectiveness of anti-diabetes medications in reducing the risk of dementia in older diabetics. Study: Comparative effectiveness of glucagon ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...

GLP-1 receptor agonists reduced obesity-related cancer incidence by 7% and all-cause mortality by 8% compared to DPP-4 inhibitors. The protective effect of GLP-1 drugs was significant for colon and ...

SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 receptor ...

MONDAY, Feb. 24, 2025 (HealthDay News) -- For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 ...